209 related articles for article (PubMed ID: 21514719)
1. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours.
Agundez M; Grau L; Palou J; Algaba F; Villavicencio H; Sanchez-Carbayo M
Eur Urol; 2011 Jul; 60(1):131-40. PubMed ID: 21514719
[TBL] [Abstract][Full Text] [Related]
2. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer.
Alvarez-Múgica M; Cebrian V; Fernández-Gómez JM; Fresno F; Escaf S; Sánchez-Carbayo M
J Urol; 2010 Oct; 184(4):1507-13. PubMed ID: 20723929
[TBL] [Abstract][Full Text] [Related]
3. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
Alvarez-Múgica M; Fernández-Gómez JM; Cebrian V; Fresno F; Escaf S; Sánchez-Carbayo M
Eur Urol; 2013 Feb; 63(2):364-70. PubMed ID: 22682992
[TBL] [Abstract][Full Text] [Related]
4. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
5. Molecular classification of non-muscle-invasive bladder cancer (pTa low-grade, pT1 low-grade, and pT1 high-grade subgroups) using methylation of tumor-suppressor genes.
Sacristan R; Gonzalez C; Fernández-Gómez JM; Fresno F; Escaf S; Sánchez-Carbayo M
J Mol Diagn; 2014 Sep; 16(5):564-572. PubMed ID: 24998186
[TBL] [Abstract][Full Text] [Related]
6. Methylation status as a predictor of intravesical Bacillus Calmette-Guérin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor.
Husek P; Pacovsky J; Chmelarova M; Podhola M; Brodak M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Jun; 161(2):210-216. PubMed ID: 28344356
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
Gontero P; Sylvester R; Pisano F; Joniau S; Vander Eeckt K; Serretta V; Larré S; Di Stasi S; Van Rhijn B; Witjes AJ; Grotenhuis AJ; Kiemeney LA; Colombo R; Briganti A; Babjuk M; Malmström PU; Oderda M; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Johansson R; Frea B; Soukup V; Xylinas E; Dalbagni G; Karnes RJ; Shariat SF; Palou J
Eur Urol; 2015 Jan; 67(1):74-82. PubMed ID: 25043942
[TBL] [Abstract][Full Text] [Related]
8. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
Boorjian SA; Zhu F; Herr HW
BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer.
Shirakawa H; Kikuchi E; Tanaka N; Matsumoto K; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Sep; 110(6 Pt B):E216-21. PubMed ID: 22313616
[TBL] [Abstract][Full Text] [Related]
10. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
[TBL] [Abstract][Full Text] [Related]
11. Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer.
Herr HW; Dalbagni G; Donat SM
Eur Urol; 2011 Jul; 60(1):32-6. PubMed ID: 21497431
[TBL] [Abstract][Full Text] [Related]
12. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
13. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
[TBL] [Abstract][Full Text] [Related]
14. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer.
Nakai Y; Nonomura N; Kawashima A; Mukai M; Nagahara A; Nakayama M; Takayama H; Nishimura K; Okuyama A
Jpn J Clin Oncol; 2010 Mar; 40(3):252-7. PubMed ID: 19995789
[TBL] [Abstract][Full Text] [Related]
15. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.
Palou J; Algaba F; Vera I; Rodriguez O; Villavicencio H; Sanchez-Carbayo M
Eur Urol; 2009 Nov; 56(5):829-36. PubMed ID: 18926620
[TBL] [Abstract][Full Text] [Related]
16. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
17. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Portillo J; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Montesinos M; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA
J Urol; 2009 Nov; 182(5):2195-203. PubMed ID: 19758621
[TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
Andius P; Holmäng S
BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
[TBL] [Abstract][Full Text] [Related]
19. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
